Allogeneic T cells Transduced with an Anti-CD19 Chimeric Antigen Receptor

Division Of Basic Sciences - Nci

Investigators

Linked publications & trials

Abstract

This trial is one of few CAR trials exclusively focused on applying anti-CD19 CAR T cells to the allogeneic transplantation setting. This trial is significant because unlike most trials of anti-CD19 chimeric antigen receptors, it does not include chemotherapy, so it gives a pure assessment of the activity of the anti-CD19 CAR T cells. We continue recruit more patients for this trial. We have obtained important information on toxicity and predictors of successful therapy with each patient. A paper covering this trial (Brudno et al.) was published in the Journal of Clinical Oncology in 2016. The project is now focused on testing less-differentiated T cells called stem memory T cells (Ttscm) transduced with an anti-CD19 CAR. In this effort, we are currently collaborating with another Investigator, Luca Gattinoni, in developing a process for administering allogeneic anti-CD19 CAR stem memory T cells. We have treated 11 patients with anti-CD19 CAR Tscm cells on this clinical trial. A patient, with acute lymphoid leukemia, obtained a complete remission after infusion of Tscm anti-CD19 CAR T cells that is ongoing. Another patient with lymphoma obtained a partial remission. This trial has now ended enrollment and a manuscript reporting the results is in preparation. Many correlative immunology experiments are in progress.